Actinium Pharmaceuticals, Inc. — Form 10-Q
Filed August 7, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 72/100
What the filing says
Actinium Pharmaceuticals signed an exclusive worldwide license agreement dated June 25, 2024, with ISU Abxis Co., Ltd. (Korean biotech) to develop and commercialize radiopharmaceutical products based on a monoclonal antibody. The agreement includes upfront and milestone payments (specific amounts redacted), royalties of [redacted]% of net sales, and transfer of cell lines and technical materials. Actinium gains exclusive rights in radiotherapy and imaging fields; ISU Abxis is restricted from competing in these fields during the term.
Why this rating
Material licensing deal: exclusive worldwide radiopharmaceutical IP adds pipeline product to ~$44M market-cap company. Strengthens core strategy. Unknown upfront/milestone amounts and redacted royalty rate limit full impact assessment, but exclusive access is strategically significant.
See more from August 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.